3OCT

Thinnest US health bench faces PHEIC

3 min read

13:42UTC

Jay Bhattacharya holds NIH Director and acting CDC Director simultaneously; Brian Christine, an Alabama urologist, is the Senate-confirmed HHS Assistant Secretary for Health since October 2025.

← Back to River boat carries Ebola 1,000 km downriver Jump to analysis ↓

ScienceDeveloping

Key takeaway

Three of the federal positions that ran 2018 Equateur have no permanent occupant today.

Brian Christine, an Alabama urologist Senate-confirmed in October 2025, holds the Assistant Secretary for Health post at the US Department of Health and Human Services, the second-ranking health official below the Secretary⁠¹. Jay Bhattacharya, confirmed as NIH Director in March 2025, has held the acting CDC Director role concurrently since shortly after confirmation. Bhattacharya posted on X in January 2024 that "the best pandemic preparedness playbook for the United States is making America healthy again"⁠²; the post remains the publicly stated approach.

When the CDC ran the 2018 Equateur response under Robert Redfield, the agency had a confirmed director, a confirmed FDA commissioner and a confirmed Office of the Assistant Secretary for Preparedness and Response head simultaneously. None of those three positions currently has a permanent occupant. An Assistant Secretary for Health from urology, paired with a single individual holding NIH and acting CDC, gives the federal public-health roster its thinnest senior bench of the post-2014 era at the first Bundibugyo PHEIC in history. The concurrent H5N1 pressure across Idaho dairy operations and Bangladesh surveillance sits on the same bench at the same time.

Deep Analysis

In plain English

In a health emergency, the United States has several key agencies: the Centers for Disease Control (CDC), the Food and Drug Administration (FDA), and the Office of the Assistant Secretary for Preparedness and Response (ASPR). Each normally has a Senate-confirmed director WHO can make major decisions and speak with authority. As of May 2026, none of those three positions has a confirmed permanent occupant. Jay Bhattacharya, the NIH Director, is also filling in as acting CDC head. The second-ranking health official, Brian Christine, is a urologist with no prior public health emergency role. That is the team managing the first Bundibugyo Ebola emergency in history, while also dealing with a bird flu surge in Idaho dairy farms {{EVREF:/t/pandemics-and-biosecurity/2/Idaho-dairy-H5N1-1-to-59-herds-in-twelve-days/}}.

What could happen next?

Risk
Multi-threat concurrent pressure across the Bundibugyo PHEIC, Idaho H5N1, and Andes hantavirus, with no confirmed leadership at CDC, FDA, or ASPR, creates conditions where interagency resource allocation decisions may be delayed or uncoordinated.
Consequence
CDC's absence from the WHO AFRO release while present in the Africa CDC statement may reflect the acting leadership's difficulty committing field resources without confirmed authority to approve budgetary deployment.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: During the 2018 Equateur Ebola outbreak, confirmed senior US public health roles were held by Robert Redfield (CDC Director, confirmed March 2018), Scott Gottlieb (FDA Commissioner, confirmed May 2017), and Robert Kadlec (ASPR, confirmed August 2017). Three confirmed senior officials at CDC, FDA, and ASPR simultaneously provided clear interagency authority lines for the response. That outbreak was contained in three months.

Counter-parallel: During the early COVID-19 response in January-March 2020, Robert Redfield was confirmed as CDC Director and Alex Azar as HHS Secretary, giving the US a fully staffed leadership bench.

The US still missed its 14 January 2020 WHO early warning, failed to scale domestic testing until late March, and did not implement coordinated PPE logistics until mid-April. Confirmed leadership is a structural prerequisite for clear decision authority; it does not guarantee effective response execution.

Consensus view: Former HHS Assistant Secretary for Preparedness and Response Robert Kadlec, WHO held confirmed roles at ASPR under three administrations, observed in public commentary that the simultaneous absence of confirmed CDC Director, FDA Commissioner, and ASPR head means outbreak-response decisions must be escalated to the HHS Secretary level for any cross-agency coordination, adding decision latency at the moment outbreak response most requires speed.

Counter-view: Former FDA Commissioner Scott Gottlieb (AEI health policy fellow) wrote in the Wall Street Journal in April 2026 that acting and interim officials can be operationally effective when career staff infrastructure remains intact, and argued that the CDC's career epidemiology and emergency response staff at the agency level have more institutional capacity than any single confirmed director.

Gottlieb's position is that personnel gaps at Senate-confirmed level matter less than programmatic budget and workforce continuity.

Key tension: Whether the acting-official structure creates real decision-latency in a multi-threat environment (Bundibugyo PHEIC + Idaho H5N1 + Andes hantavirus) or whether Gottlieb's career-staff argument holds when all three threats compete for the same budget and interagency attention simultaneously.

Sources:Wikipedia / Senate records / CNN Politics·Wikipedia / Senate records / CNN Politics·Science-Based Medicine (citing Bhattacharya's X post)

Mentions:Jay Bhattacharya →Brian Christine →NIH →United States →Bangladesh →H5N1 →Idaho →Wall Street Journal →PHEIC →Alabama →World Health Organization →Bundibugyo ebolavirus →HHS →CDC →

First Reported In

Update #3 · WHO calls Ebola PHEIC, no treatment exists

Wikipedia / Senate records / CNN Politics· 17 May 2026

Read original →

Causes and effects

This Event

Thinnest US health bench faces PHEIC

Three of the federal positions that ran 2018 Equateur, the CDC Director, the FDA Commissioner and the ASPR head, have no permanent occupant at the first Bundibugyo PHEIC.

Led to

Kenyan court halts US quarantine site

The dual NIH/acting-CDC role (ID:3364) is part of the thin US public-health bench context for the unilateral quarantine and screening decisions.

Occurred 29 May 2026

Read story →

Different Perspectives

IGWG co-chair Tovar da Silva Nunes

The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.

Fraport

The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.

European Centre for Disease Prevention and Control

ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.

Pan American Health Organization

PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.

Bangladesh Directorate General of Health Services

The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.

Minapharm

The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.